Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior.

Full top-line data from this trial were presented yesterday for the first time as an oral presentation (abstract #1662) at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives, in Salzburg, Austria, by the study's lead investigator, Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.

New data presented in Salzburg included the magnitude and levels of statistical significance by which the Dimebon-treated patients outperformed the placebo-treated patients on the Mini Mental State Exam (MMSE: p<0.0001), the Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL: p=0.002), and the Neuropsychiatric Inventory (NPI: p=0.006). As previously reported, Dimebon-treated patients also demonstrated significant improvement versus placebo on both the primary and key secondary endpoints in this study -- the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog: p<0.0001) and the Clinician's Interview-Based Impression of Change with a caregiver interview (CIBIC-plus: p<0.0001). Dimebon was well tolerated in this study.

"In my experience, the results of this study are particularly striking for two primary reasons," said Dr. Doody. "First, Dimebon produced statistically significant improvement over pl
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... Calif., April 14 Researchers at,the Barbara ... been studying,racial disparities related to cancer patients. ... (AACR) Annual Meeting, Karmanos researchers,Vitaly Balan, Ph.D., ... their abstract, Galectin-3 nsSNP rs4644 Foretells Human ...
... 14 Perrigo Company,(Nasdaq: PRGO ; ... final approval,from the U.S. Food and Drug ... Cetirizine Hydrochloride Oral Solution,(Allergy) and Children,s Cetirizine ... will be marketed under store brand labels ...
Cached Medicine Technology:Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 2Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 3Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution 2
(Date:9/19/2014)... leading Dartmouth researcher, working with The Melanoma Genetics Consortium, ... today in the Journal of the National Cancer ... of melanoma. , "For the first time, we have ... telomeres play a part in the risk of developing ... PhD, School of Medicine at the University of Leeds ...
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... The U.S. Food and Drug Administration approved a new type ... a class of once-a-week injectable drugs that help manage blood ... "Trulicity is a new treatment option, which can be used ... sugar levels in the overall management of type 2 diabetes," ... Drug Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... 2014 MetroMD, a leading anti-ageing clinic has ... of human health. This therapy has grown tremendously across USA ... more effective, safe and dependable. It has far reaching benefits ... to live a very healthy and active lifestyle even beyond ... therapy, a senior therapist at MetroMD said, “HGH or Human ...
(Date:9/19/2014)... - New research published today in the online journal ... reach 6,800 in West Africa by the end of ... , Arizona State University and Harvard University researchers ... rise in cases significantly increased in August in Liberia ... was put in place, indicating that the mass quarantine ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2
... April 2010 - Elsevier, the world-leading publisher of ... proudly announces the release of a brand-new single ... mitral valve disease by the internationally renowned cardiac ... will launch at the 90th Annual Meeting of ...
... ... and printing products, today announced it is ready for immediate shipping of thousands of ... through customer service or instantly online from the company’s award winning web site My1Stop.com. ... Ft. Scott, ...
... ... money with FatWallet’s expert selection of deals for Mother’s Day. Experienced experts research the ... and seasonal categories such as laptops, HDTVs, Father’s Day and graduation. , ... (PRWEB) April 26, 2010 -- ...
... ... Documentation by Integrating Electronic Medical Forms Generated During the Pre-operative Process into Core ... ... important new level of clinical integration designed to provide immediate access to patient ...
... ... area residents safe and effective cosmetic and aesthetic treatments. Advanced Aesthetics utilizes top ... ... The art of aesthetics is continually changing. As technology progresses, innovative treatments replace ...
... that factors known to increase the risk of breast cancer ... Published early online in Cancer , a peer-reviewed journal ... is needed to evaluate how breast cancer risk factors differ ... frequently in certain ethnic and racial groups, but the reasons ...
Cached Medicine News:Health News:Elsevier launches Carpentier's reconstructive valve surgery book 2Health News:My1Stop.com New Packaging Supplies Offering for Distribution Centers and Small Business Shipping 2Health News:Expert Approved: FatWallet Guides Mother's Day Shoppers to the Best Deals Online 2Health News:SourceMedical Provides Ambulatory Surgery Centers with New Levels of Document Integration for Easy Access to Patient Data 2Health News:SourceMedical Provides Ambulatory Surgery Centers with New Levels of Document Integration for Easy Access to Patient Data 3Health News:In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics 2Health News:In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics 3Health News:Breast cancer risk factors differ among races 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
Medicine Products: